{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T23:48:38Z","timestamp":1770508118671,"version":"3.49.0"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,2,15]]},"DOI":"10.1093\/cid\/ciu868","type":"journal-article","created":{"date-parts":[[2014,11,1]],"date-time":"2014-11-01T07:13:22Z","timestamp":1414826002000},"page":"549-556","source":"Crossref","is-referenced-by-count":61,"title":["Pharmacokinetics and Safety of Moxifloxacin in Children With Multidrug-Resistant Tuberculosis"],"prefix":"10.1093","volume":"60","author":[{"given":"Stephanie","family":"Thee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony J.","family":"Garcia-Prats","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heather R.","family":"Draper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helen M.","family":"McIlleron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lubbe","family":"Wiesner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"Castel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H. Simon","family":"Schaaf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anneke C.","family":"Hesseling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2014,10,30]]},"reference":[{"key":"key\n\t\t\t\t20170522094457_CIU868C1","article-title":"Global tuberculosis report 2013","author":"World Health Organization"},{"key":"key\n\t\t\t\t20170522094457_CIU868C2","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1016\/S0140-6736(14)60195-1","article-title":"Incidence of multidrug-resistant tuberculosis disease in children: systematic review and global estimates","volume":"383","year":"2014","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20170522094457_CIU868C3","doi-asserted-by":"crossref","first-page":"e105346","DOI":"10.1371\/journal.pone.0105346","article-title":"Enhancing TB case detection: experience in offering upfront Xpert MTB\/RIF testing to pediatric presumptive TB and DR TB cases for early rapid diagnosis of drug sensitive and drug resistant TB","volume":"9","year":"2014","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t20170522094457_CIU868C4","article-title":"Guidelines for the programmatic management of drug-resistant tuberculosis\u20142011 update","author":"World Health Organization"},{"key":"key\n\t\t\t\t20170522094457_CIU868C5","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/S0924-8579(02)00239-X","article-title":"In vitro activity of moxifloxacin, levofloxacin, gatifloxacin and linezolid against Mycobacterium tuberculosis","volume":"20","year":"2002","journal-title":"Int J Antimicrob Agents"},{"key":"key\n\t\t\t\t20170522094457_CIU868C6","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1164\/rccm.201206-1001CI","article-title":"Caring for children with drug-resistant tuberculosis: practice-based recommendations","volume":"186","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"key":"key\n\t\t\t\t20170522094457_CIU868C7","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1128\/AAC.00414-06","article-title":"Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy","volume":"51","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20170522094457_CIU868C8","first-page":"605","article-title":"Early and extended early bactericidal activity of levofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis","volume":"10","year":"2006","journal-title":"Int J Tuberc Lung Dis"},{"key":"key\n\t\t\t\t20170522094457_CIU868C9","first-page":"65","article-title":"Adding moxifloxacin is associated with a shorter time to culture conversion in pulmonary tuberculosis","volume":"14","year":"2010","journal-title":"Int J Tuberc Lung Dis"},{"key":"key\n\t\t\t\t20170522094457_CIU868C10","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1183\/09031936.00176610","article-title":"Evaluation of moxifloxacin for the treatment of tuberculosis: 3 years of experience","volume":"38","year":"2011","journal-title":"Eur Respir J"},{"key":"key\n\t\t\t\t20170522094457_CIU868C11","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1086\/521894","article-title":"Rifampicin reduces plasma concentrations of moxifloxacin in patients with tuberculosis","volume":"45","year":"2007","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20170522094457_CIU868C12","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1128\/AAC.01036-07","article-title":"Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis","volume":"52","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20170522094457_CIU868C13","doi-asserted-by":"crossref","first-page":"4471","DOI":"10.1128\/AAC.00404-12","article-title":"Moxifloxacin population pharmacokinetics in patients with pulmonary tuberculosis and the effect of intermittent high-dose rifapentine","volume":"56","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20170522094457_CIU868C14","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1183\/09031936.00202411","article-title":"Moxifloxacin in multidrug-resistant tuberculosis: is there any indication for therapeutic drug monitoring?","volume":"40","year":"2012","journal-title":"Eur Respir J"},{"key":"key\n\t\t\t\t20170522094457_CIU868C15","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S1473-3099(12)70264-5","article-title":"Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis: an open-label, randomised controlled phase 2 trial","volume":"13","year":"2013","journal-title":"Lancet Infect Dis"},{"issue":"suppl 1","key":"key\n\t\t\t\t20170522094457_CIU868C16","first-page":"33","article-title":"Effects of dairy products on the oral bioavailability of moxifloxacin, a novel 8-methoxyfluoroquinolone, in healthy volunteers","volume":"40","year":"2001","journal-title":"Clin Pharmacokinet"},{"issue":"suppl B","key":"key\n\t\t\t\t20170522094457_CIU868C17","first-page":"83","article-title":"Pharmacokinetics and elimination of moxifloxacin after oral and intravenous administration in man","volume":"43","year":"1999","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20170522094457_CIU868C18","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S1472-9792(08)70016-7","article-title":"Moxifloxacin","volume":"88","year":"2008","journal-title":"Tuberculosis (Edinb)"},{"key":"key\n\t\t\t\t20170522094457_CIU868C19","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1136\/thoraxjnl-2013-203900","article-title":"High treatment success in children treated for multidrug-resistant tuberculosis: an observational cohort study","volume":"69","year":"2014","journal-title":"Thorax"},{"key":"key\n\t\t\t\t20170522094457_CIU868C20","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1002\/ppul.22755","article-title":"Moxifloxacin for the treatment of pulmonary tuberculosis in children: a single center experience","volume":"49","year":"2014","journal-title":"Pediatr Pulmonol"},{"key":"key\n\t\t\t\t20170522094457_CIU868C21","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1097\/INF.0b013e31823980c3","article-title":"Pharmacokinetics of moxifloxacin in an infant with Mycoplasma hominis meningitis","volume":"31","year":"2012","journal-title":"Pediatr Infect Dis J"},{"issue":"suppl 2","key":"key\n\t\t\t\t20170522094457_CIU868C22","doi-asserted-by":"crossref","first-page":"S199","DOI":"10.1093\/infdis\/jis008","article-title":"Evaluation of tuberculosis diagnostics in children: 1. Proposed clinical case definitions for classification of intrathoracic tuberculosis disease. Consensus from an expert panel","volume":"205","year":"2012","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20170522094457_CIU868C23","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1093\/jac\/dks033","article-title":"gyrA mutations and phenotypic susceptibility levels to ofloxacin and moxifloxacin in clinical isolates of Mycobacterium tuberculosis","volume":"67","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20170522094457_CIU868C24","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1046\/j.1542-474X.2003.08413.x","article-title":"The duration of systole in an electrocardiogram in normal humans and in patients with heart disease. 1920","volume":"8","year":"2003","journal-title":"Ann Noninvasive Electrocardiol"},{"key":"key\n\t\t\t\t20170522094457_CIU868C25","doi-asserted-by":"crossref","first-page":"5560","DOI":"10.1128\/AAC.05429-11","article-title":"Pharmacokinetics of isoniazid, rifampin, and pyrazinamide in children younger than two years of age with tuberculosis: evidence for implementation of revised World Health Organization recommendations","volume":"55","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20170522094457_CIU868C26","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1741-7015-7-19","article-title":"Rifampin pharmacokinetics in children, with and without human immunodeficiency virus infection, hospitalized for the management of severe forms of tuberculosis","volume":"7","year":"2009","journal-title":"BMC Med"},{"key":"key\n\t\t\t\t20170522094457_CIU868C27","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1128\/AAC.50.2.407-413.2006","article-title":"Low levels of pyrazinamide and ethambutol in children with tuberculosis and impact of age, nutritional status, and human immunodeficiency virus infection","volume":"50","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20170522094457_CIU868C28","doi-asserted-by":"crossref","first-page":"2948","DOI":"10.1128\/AAC.02755-13","article-title":"Pharmacokinetics of ofloxacin and levofloxacin for prevention and treatment of multidrug-resistant tuberculosis in children","volume":"58","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20170522094457_CIU868C29","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1136\/archdischild-2013-303720","article-title":"Understanding dosing: children are small adults, neonates are immature children","volume":"98","year":"2013","journal-title":"Arch Dis Child"},{"key":"key\n\t\t\t\t20170522094457_CIU868C30","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1517\/17425255.1.3.447","article-title":"Differences in absorption, distribution, metabolism and excretion of xenobiotics between the paediatric and adult populations","volume":"1","year":"2005","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"key\n\t\t\t\t20170522094457_CIU868C31","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1086\/380795","article-title":"Malabsorption of rifampin and isoniazid in HIV-infected patients with and without tuberculosis","volume":"38","year":"2004","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20170522094457_CIU868C32","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1086\/315708","article-title":"Selection of antibiotic-resistant bacterial mutants: allelic diversity among fluoroquinolone-resistant mutations","volume":"182","year":"2000","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20170522094457_CIU868C33","doi-asserted-by":"crossref","first-page":"e1253","DOI":"10.1542\/peds.2009-2172","article-title":"Two pediatric cases of multidrug-resistant tuberculosis treated with linezolid and moxifloxacin","volume":"126","year":"2010","journal-title":"Pediatrics"},{"key":"key\n\t\t\t\t20170522094457_CIU868C34","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1097\/INF.0b013e318269cc6a","article-title":"Treatment of tuberculosis with levofloxacin or moxifloxacin: report of 6 pediatric cases","volume":"31","year":"2012","journal-title":"Pediatr Infect Dis J"},{"issue":"suppl 1","key":"key\n\t\t\t\t20170522094457_CIU868C35","first-page":"S141","article-title":"Specific toxicologic aspects of the quinolones","volume":"10","year":"1988","journal-title":"Rev Infect Dis"},{"key":"key\n\t\t\t\t20170522094457_CIU868C36","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1097\/INF.0b013e3180cc20e4","article-title":"Will fluoroquinolones ever be recommended for common infections in children?","volume":"26","year":"2007","journal-title":"Pediatr Infect Dis J"},{"key":"key\n\t\t\t\t20170522094457_CIU868C37","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1097\/01.inf.0000101994.25947.12","article-title":"Safety profile of quinolone antibiotics in the pediatric population","volume":"22","year":"2003","journal-title":"Pediatr Infect Dis J"},{"key":"key\n\t\t\t\t20170522094457_CIU868C38","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/S1473-3099(11)70366-8","article-title":"Management of children exposed to multidrug-resistant Mycobacterium tuberculosis","volume":"12","year":"2012","journal-title":"Lancet Infect Dis"},{"key":"key\n\t\t\t\t20170522094457_CIU868C39","doi-asserted-by":"crossref","first-page":"912","DOI":"10.5588\/ijtld.13.0028","article-title":"Treatment for LTBI in contacts of MDR-TB patients, Federated States of Micronesia, 2009\u20132012","volume":"18","year":"2014","journal-title":"Int J Tuberc Lung Dis"},{"key":"key\n\t\t\t\t20170522094457_CIU868C40","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1124\/mol.59.1.122","article-title":"Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG","volume":"59","year":"2001","journal-title":"Mol Pharmacol"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","deposited":{"date-parts":[[2019,8,16]],"date-time":"2019-08-16T22:44:21Z","timestamp":1565995461000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article-lookup\/doi\/10.1093\/cid\/ciu868"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10,30]]},"references-count":40,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2014,10,30]]},"published-print":{"date-parts":[[2015,2,15]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciu868","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,10,30]]}}}